Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer
January 14, 2020 07:00 ET
|
G1 Therapeutics
SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a...
G1 Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
January 07, 2020 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)
December 11, 2019 18:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase...
G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019
November 26, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics to Present at Stifel Healthcare Conference on November 19, 2019
November 12, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
G1 Therapeutics Provides Third Quarter 2019 Corporate and Financial Update
November 05, 2019 16:00 ET
|
G1 Therapeutics
Company to complete New Drug Application (NDA) submission for trilaciclib in small cell lung cancer in 2Q20 Phase 2 trilaciclib data and Phase 1 G1T48 data presented at ESMO Management to host webcast...
G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019
October 29, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019
September 29, 2019 06:00 ET
|
G1 Therapeutics
-- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1...
G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival
September 28, 2019 04:15 ET
|
G1 Therapeutics
-- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung...
G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress
September 10, 2019 06:01 ET
|
G1 Therapeutics
- Company to present first clinical data on oral SERD G1T48 in breast cancer - - Overall survival data on trilaciclib in women with metastatic triple-negative breast cancer (mTNBC) accepted for...